Elicitation of health state utilities in neuroendocrine tumours

Journal of Medical Economics

Volumn 15, Issue 4, 2012, Pages 681-687

  Swinburn, P ^a   Wang, J ^b   Chandiwana, D ^b   Mansoor, W ^c   Lloyd, A ^a  

^a ICON PLC   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Neuroendocrine tumour; Quality of life; Utility

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG ERUPTION; FEMALE; HAND FOOT SYNDROME; HEALTH STATUS; HUMAN; HYPERGLYCEMIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; PNEUMONIA; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; TUMOR GROWTH; VIGNETTE;

ADULT; FEMALE; GREAT BRITAIN; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PATIENT PREFERENCE; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRES; RARE DISEASES; YOUNG ADULT;

EID: 84862580812     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.670175     Document Type: Article

References (22)

1. Yao JC, Hassan M, Phan A, et al. One-hundred years after ''carcinoid'': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:2063-3072
2. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458-511 (Pubitemid 38780668)
3. Yim KL. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocr 2011; 40:181-186
4. Buchanan KD, Johnston CF, O'Hare MM, et al. Neuroendocrine tumors. A European view. Am J Med 1986;81:14-22
5. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 2011;29:934-43
6. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2012;8:54-64
7. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: OUP, 2005
8. National Institute for Health & Clinical Excellence (NICE). Guide to the methods of technology appraisal, NICE: London, UK June 2008 http://www.nice.org. uk/niceMedia/pdf/TAP-Methods.pdf. Accessed January 15, 2010
9. Lloyd A, Wild D, Gallop K, et al. Reimbursement agency requirements for health related quality-of-life data: a case study. Expert Rev Pharmacoecon Outcomes Res 2009;9:527-37
10. Brooks R. EuroQol: the current state of play. Health Policy 1996;7:53-72 (Pubitemid 26191458)
11. Torrance GW, Thomas WH, Sackett DL. A utility maximization model of evaluation of health care programs. Health Serv Res 1972;7:118-33
12. Davies AH, Larsson G, Ardill J, et al. Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer 2006;42:477-84 (Pubitemid 43227926)
13. Frö jd C, Larsson G, Lampic C, et al. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective and comparative study. Health Qual Life Outcomes 2007;5:18
14. Haugland T, Vatn MH, Veenstra M, et al. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res 2009;18:719-26
15. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 2004;22:2724-9 (Pubitemid 41103761)
16. Office of National Statistics. Population of the United Kingdom: by ethnic group. National Statistics website, 2001. http://www.statistics.gov.uk/ CCI/nugget.asp?ID273. Accessed January 15, 2010
17. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30 (Pubitemid 16098443)
18. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316:736-41 (Pubitemid 28121072)
19. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009;45:1397-406
20. Esnaola NF, Lazarides SN, Mentzer SJ, et al. Outcomes and costeffectiveness of alternative staging strategies for non-small-cell lung cancer. J Clin Oncol 2002;20:263-73 (Pubitemid 34032620)
21. Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009; 25:401-11
22. Scottish Medical Consortium. Advice for the use of Sutent in the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. 2011 http://www.scottishmedicines. org.uk/SMC-Advice/Advice/698-11-sunitinib-Sutent- with-PAS/sunitinib-Sutent-with-PAS. Accessed September 30, 2011